{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:29:31Z","timestamp":1786321771144,"version":"build-2736575974"},"reference-count":208,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01488-w","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T18:17:13Z","timestamp":1779214633000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Decoding the crosstalk between ubiquitination and other post-translational modifications in cancer immunity: from mechanisms to clinical prospects"],"prefix":"10.1038","volume":"10","author":[{"given":"Kai-Qiang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Qi","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Zhu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe-Ming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Qiu","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"1488_CR1","doi-asserted-by":"publisher","first-page":"1229397","DOI":"10.3389\/fimmu.2023.1229397","volume":"14","author":"Y Li","year":"2023","unstructured":"Li, Y., Zhang, R. & Hei, H. Advances in post-translational modifications of proteins and cancer immunotherapy. Front. Immunol. 14, 1229397 (2023).","journal-title":"Front. Immunol."},{"key":"1488_CR2","doi-asserted-by":"publisher","first-page":"1230135","DOI":"10.3389\/fimmu.2023.1230135","volume":"14","author":"C Feng","year":"2023","unstructured":"Feng, C., Zhang, L., Chang, X., Qin, D. & Zhang, T. Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy. Front. Immunol. 14, 1230135 (2023).","journal-title":"Front. Immunol."},{"key":"1488_CR3","doi-asserted-by":"crossref","unstructured":"Poniewierska-Baran, A., Sobolak, K., Nied\u017awiedzka-Rystwej, P., Plewa, P. & Pawlik, A. Immunotherapy based on immune checkpoint molecules and immune checkpoint inhibitors in gastric cancer-narrative review. Int. J. Mol. Sci. 25, 6471 (2024).","DOI":"10.3390\/ijms25126471"},{"key":"1488_CR4","doi-asserted-by":"crossref","unstructured":"Cheng, B. et al. Small molecule inhibitors targeting PD-L1, CTLA4, VISTA, TIM-3, and LAG3 for cancer immunotherapy (2020\u20132024). Eur. J. Med. Chem. 283,117141 (2025).","DOI":"10.1016\/j.ejmech.2024.117141"},{"key":"1488_CR5","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","volume":"33","author":"KK Patel","year":"2025","unstructured":"Patel, K. K., Tariveranmoshabad, M., Kadu, S., Shobaki, N. & June, C. From concept to cure: the evolution of CAR-T cell therapy. Mol. Ther. 33, 2123\u20132140 (2025).","journal-title":"Mol. Ther."},{"key":"1488_CR6","doi-asserted-by":"crossref","unstructured":"Ruzzi, F. et al. Cancer vaccines: target antigens, vaccine platforms and preclinical models. Mol. Asp. Med. 101, 101324 (2025).","DOI":"10.1016\/j.mam.2024.101324"},{"key":"1488_CR7","doi-asserted-by":"crossref","unstructured":"Kaczmarek, M. et al. Cancer vaccine therapeutics: limitations and effectiveness\u2014a literature review. Cells 12,12172159 (2023).","DOI":"10.3390\/cells12172159"},{"key":"1488_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2024.11.011","volume":"43","author":"CT Kureshi","year":"2025","unstructured":"Kureshi, C. T. & Dougan, S. K. Cytokines in cancer. Cancer Cell 43, 15\u201335 (2025).","journal-title":"Cancer Cell"},{"key":"1488_CR9","doi-asserted-by":"crossref","unstructured":"Yu, R., Zhu, B. & Chen, D. Type I interferon-mediated tumor immunity and its role in immunotherapy. Cell. Mol. Life Sci. 79, 191 (2022).","DOI":"10.1007\/s00018-022-04219-z"},{"key":"1488_CR10","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1488_CR11","doi-asserted-by":"publisher","first-page":"216758","DOI":"10.1016\/j.canlet.2024.216758","volume":"588","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. Unleashing the power of immune checkpoints: post-translational modification of novel molecules and clinical applications. Cancer Lett. 588, 216758 (2024).","journal-title":"Cancer Lett."},{"key":"1488_CR12","doi-asserted-by":"crossref","unstructured":"Chong, X. et al. Recent developments in immunotherapy for gastrointestinal tract cancers. J. Hematol. Oncol. 17, 65 (2024).","DOI":"10.1186\/s13045-024-01578-x"},{"key":"1488_CR13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","volume":"25","author":"M Roerden","year":"2025","unstructured":"Roerden, M. & Spranger, S. Cancer immune evasion, immunoediting and intratumour heterogeneity. Nat. Rev. Immunol. 25, 353\u2013369 (2025).","journal-title":"Nat. Rev. Immunol."},{"key":"1488_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s10020-023-00684-9","volume":"29","author":"YH Yang","year":"2023","unstructured":"Yang, Y. H., Wen, R., Yang, N., Zhang, T. N. & Liu, C. F. Roles of protein post-translational modifications in glucose and lipid metabolism: mechanisms and perspectives. Mol. Med. 29, 93 (2023).","journal-title":"Mol. Med."},{"key":"1488_CR15","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.tibs.2025.07.006","volume":"50","author":"F Chu","year":"2025","unstructured":"Chu, F., Sharma, S., Ginsberg, S. D. & Chiosis, G. PTMs as molecular encoders: reprogramming chaperones into epichaperomes for network control in disease. Trends Biochem. Sci. 50, 892\u2013905 (2025).","journal-title":"Trends Biochem. Sci."},{"key":"1488_CR16","doi-asserted-by":"publisher","first-page":"108749","DOI":"10.1016\/j.pharmthera.2024.108749","volume":"265","author":"Y Cao","year":"2025","unstructured":"Cao, Y. et al. Exploring the landscape of post-translational modification in drug discovery. Pharm. Ther. 265, 108749 (2025).","journal-title":"Pharm. Ther."},{"key":"1488_CR17","doi-asserted-by":"crossref","unstructured":"Zhang, X. et al. DNA damage-induced proteasome phosphorylation controls substrate recognition and facilitates DNA repair. Proc. Natl. Acad. Sci. USA. 121, e2321204121 (2024).","DOI":"10.1073\/pnas.2321204121"},{"key":"1488_CR18","doi-asserted-by":"crossref","unstructured":"Wang, M., Shi, Y., Liang, Z. & Yang, F. USP7 promotes the malignant progression of osteosarcoma through the KPNA2\/PKLR axis. Cell. Signal. 132, 111819 (2025).","DOI":"10.1016\/j.cellsig.2025.111819"},{"key":"1488_CR19","doi-asserted-by":"crossref","unstructured":"Zhou, S. et al. Indole-3-lactic acid suppresses colorectal cancer via metabolic reprogramming. Gut Microbes. 17, 2508949 (2025).","DOI":"10.1080\/19490976.2025.2508949"},{"key":"1488_CR20","doi-asserted-by":"publisher","first-page":"123437","DOI":"10.1016\/j.biomaterials.2025.123437","volume":"323","author":"L Zhang","year":"2025","unstructured":"Zhang, L. et al. Dual inhibition of oxidative phosphorylation and glycolysis using a hyaluronic acid nanoparticle NOX inhibitor enhanced response to radiotherapy in colorectal cancer. Biomaterials 323, 123437 (2025).","journal-title":"Biomaterials"},{"key":"1488_CR21","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.molcel.2025.02.011","volume":"85","author":"M Iozzo","year":"2025","unstructured":"Iozzo, M., Pardella, E., Giannoni, E. & Chiarugi, P. The role of protein lactylation: a kaleidoscopic post-translational modification in cancer. Mol. Cell 85, 1263\u20131279 (2025).","journal-title":"Mol. Cell"},{"key":"1488_CR22","doi-asserted-by":"crossref","unstructured":"Shu, F. et al. Epigenetic and post-translational modifications in autophagy: biological functions and therapeutic targets. Signal Transduct. Target. Ther. 8, 32 (2023).","DOI":"10.1038\/s41392-022-01300-8"},{"key":"1488_CR23","doi-asserted-by":"publisher","first-page":"20220243","DOI":"10.1098\/rstb.2022.0243","volume":"378","author":"K Harada","year":"2023","unstructured":"Harada, K., Carr, S. M., Shrestha, A. & La Thangue, N. B. Citrullination and the protein code: crosstalk between post-translational modifications in cancer. Philos. Trans. R. Soc. Lond. B Biol. Sci. 378, 20220243 (2023).","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"1488_CR24","doi-asserted-by":"crossref","unstructured":"Wei, B., Yang, F., Yu, L. & Qiu, C. Crosstalk between SUMOylation and other post-translational modifications in breast cancer. Cell. Mol. Biol. Lett. 29, 107 (2024).","DOI":"10.1186\/s11658-024-00624-3"},{"key":"1488_CR25","doi-asserted-by":"publisher","first-page":"108138","DOI":"10.1016\/j.abb.2019.108138","volume":"676","author":"Z Wu","year":"2019","unstructured":"Wu, Z., Huang, R. & Yuan, L. Crosstalk of intracellular post-translational modifications in cancer. Arch. Biochem. Biophys. 676, 108138 (2019).","journal-title":"Arch. Biochem. Biophys."},{"key":"1488_CR26","doi-asserted-by":"publisher","first-page":"100129","DOI":"10.1016\/j.mcpro.2021.100129","volume":"20","author":"M Leutert","year":"2021","unstructured":"Leutert, M., Entwisle, S. W. & Vill\u00e9n, J. Decoding post-translational modification crosstalk with proteomics. Mol. Cell. Proteom. 20, 100129 (2021).","journal-title":"Mol. Cell. Proteom."},{"key":"1488_CR27","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/pmic.201300344","volume":"14","author":"AS Venne","year":"2014","unstructured":"Venne, A. S., Kollipara, L. & Zahedi, R. P. The next level of complexity: crosstalk of posttranslational modifications. Proteomics 14, 513\u2013524 (2014).","journal-title":"Proteomics"},{"key":"1488_CR28","doi-asserted-by":"crossref","unstructured":"Deng, C. et al. The role of cGAS\u2013STING pathway ubiquitination in innate immunity and multiple diseases. Front. Immunol. 16, 1522200 (2025).","DOI":"10.3389\/fimmu.2025.1522200"},{"key":"1488_CR29","doi-asserted-by":"publisher","first-page":"1339510","DOI":"10.3389\/fimmu.2024.1339510","volume":"15","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. ASFV pA151R negatively regulates type I IFN production via degrading E3 ligase TRAF6. Front. Immunol. 15, 1339510 (2024).","journal-title":"Front. Immunol."},{"key":"1488_CR30","doi-asserted-by":"crossref","unstructured":"Li, W., Li, F., Zhang, X., Lin, H.-K. & Xu, C. Insights into the post-translational modification and its emerging role in shaping the tumor microenvironment. Signal Transduct. Target. Ther. 6, 422 (2021).","DOI":"10.1038\/s41392-021-00825-8"},{"key":"1488_CR31","doi-asserted-by":"crossref","unstructured":"Sun, D. et al. CXCL5 impedes CD8+ T cell immunity by upregulating PD-L1 expression in lung cancer via PXN\/AKT signaling phosphorylation and neutrophil chemotaxis. J. Exp. Clin. Cancer Res. 43, 202 (2024).","DOI":"10.1186\/s13046-024-03122-8"},{"key":"1488_CR32","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1158\/0008-5472.CAN-23-2664","volume":"84","author":"TA Lee","year":"2024","unstructured":"Lee, T. A. et al. Post-translational modification of PD-1: potential targets for cancer immunotherapy. Cancer Res. 84, 800\u2013807 (2024).","journal-title":"Cancer Res."},{"key":"1488_CR33","doi-asserted-by":"crossref","unstructured":"Kufer, T. A. et al. MARCH1-mediated ubiquitination of MHC II impacts the MHC I antigen presentation pathway. PLoS ONE 13, e0200540 (2018).","DOI":"10.1371\/journal.pone.0200540"},{"key":"1488_CR34","doi-asserted-by":"crossref","unstructured":"Wei, C. et al. Nuclear mitochondrial acetyl-CoA acetyltransferase 1 orchestrates natural killer cell-dependent antitumor immunity in colorectal cancer. Signal Transduct. Target. Ther. 10, 138 (2025).","DOI":"10.1038\/s41392-025-02221-y"},{"key":"1488_CR35","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.7150\/thno.69444","volume":"12","author":"Y Zhou","year":"2022","unstructured":"Zhou, Y. et al. HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer. Theranostics 12, 2080\u20132094 (2022).","journal-title":"Theranostics"},{"key":"1488_CR36","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1080\/15548627.2022.2148432","volume":"19","author":"F Yi","year":"2022","unstructured":"Yi, F. et al. Regulation of RB1CC1\/FIP200 stability and autophagy function by CREBBP-mediated acetylation in an intrinsically disordered region. Autophagy 19, 1662\u20131677 (2022).","journal-title":"Autophagy"},{"key":"1488_CR37","doi-asserted-by":"crossref","unstructured":"Pan, B. et al. N-glycosylated LT\u03b2R increases the Th17\/Treg cell ratio in liver cancer by blocking RORC ubiquitination and FOXP3 transcription. Cell Death Dis. 16, 421 (2025).","DOI":"10.1038\/s41419-025-07738-2"},{"key":"1488_CR38","doi-asserted-by":"crossref","unstructured":"Liu, F. et al. Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches. Mol. Cancer 23, 148 (2024).","DOI":"10.1186\/s12943-024-02046-3"},{"key":"1488_CR39","doi-asserted-by":"crossref","unstructured":"Zhou, X. & Sun, S.-C. Targeting ubiquitin signaling for cancer immunotherapy. Signal Transduct. Target. Ther. 6, 16 (2021).","DOI":"10.1038\/s41392-020-00421-2"},{"key":"1488_CR40","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1038\/s41388-025-03594-8","volume":"44","author":"L Wu","year":"2025","unstructured":"Wu, L. et al. METAP2 inhibits K48-linked ubiquitination of YTHDF2 to promote ovarian cancer progression. Oncogene 44, 4505\u20134519 (2025).","journal-title":"Oncogene"},{"key":"1488_CR41","doi-asserted-by":"publisher","first-page":"218337","DOI":"10.1016\/j.canlet.2026.218337","volume":"645","author":"Y Sun","year":"2026","unstructured":"Sun, Y. et al. Nutrient deprivation promotes bladder cancer metastasis through Beclin-1 deacetylation-mediated autophagy activation. Cancer Lett. 645, 218337 (2026).","journal-title":"Cancer Lett."},{"key":"1488_CR42","doi-asserted-by":"crossref","unstructured":"Guo, Y. et al. Loss of TRIM31 promotes breast cancer progression through regulating K48- and K63-linked ubiquitination of p53. Cell Death Dis. 12, 945 (2021).","DOI":"10.1038\/s41419-021-04208-3"},{"key":"1488_CR43","doi-asserted-by":"crossref","unstructured":"Li, W. et al. UBE2C-induced crosstalk between mono- and polyubiquitination of SNAT2 promotes lymphatic metastasis in bladder cancer. J. Clin. Investig. 134, e179122 (2024).","DOI":"10.1172\/JCI179122"},{"key":"1488_CR44","doi-asserted-by":"publisher","first-page":"114960","DOI":"10.1016\/j.celrep.2024.114960","volume":"43","author":"D Fonseca","year":"2024","unstructured":"Fonseca, D., Pisanelli, G., Seoane, R., Miorin, L. & Garc\u00eda-Sastre, A. TRIM65 regulates innate immune signaling by enhancing K6-linked ubiquitination of IRF3 and its chromatin recruitment. Cell Rep. 43, 114960 (2024).","journal-title":"Cell Rep."},{"key":"1488_CR45","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41418-025-01592-7","volume":"33","author":"S Zhou","year":"2026","unstructured":"Zhou, S., Li, Y., Wang, C., Zhao, Y. & Zheng, X. K11- and K29-ubiquitination-mediated nuclear translocation of glycolytic enzyme aldolase A promotes pancreatic cancer progression by NF-\u03baB activation. Cell Death Differ. 33, 496\u2013511 (2026).","journal-title":"Cell Death Differ."},{"key":"1488_CR46","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s41556-026-01886-z","volume":"28","author":"A Betrancourt","year":"2026","unstructured":"Betrancourt, A. et al. Lysine-11 ubiquitination drives type-I\/III interferon induction by cGAS-STING and Toll-like receptors 3 and 4. Nat. Cell Biol. 28, 608\u2013621 (2026).","journal-title":"Nat. Cell Biol."},{"key":"1488_CR47","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41594-025-01697-0","volume":"33","author":"Q Jiang","year":"2026","unstructured":"Jiang, Q. et al. TRIM21 and OTUD6A orchestrate AKT K27-linked atypical ubiquitination to modulate cancer chemoresistance. Nat. Struct. Mol. Biol. 33, 84\u201399 (2026).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1488_CR48","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.ymthe.2020.12.032","volume":"29","author":"X Hu","year":"2021","unstructured":"Hu, X. et al. Emerging role of ubiquitination in the regulation of PD-1\/PD-L1 in cancer immunotherapy. Mol. Ther. 29, 908\u2013919 (2021).","journal-title":"Mol. Ther."},{"key":"1488_CR49","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1158\/0008-5472.CAN-23-3513","volume":"84","author":"C Zhang","year":"2024","unstructured":"Zhang, C. et al. H3K18 lactylation potentiates immune escape of non-small cell lung cancer. Cancer Res. 84, 3589\u20133601 (2024).","journal-title":"Cancer Res."},{"key":"1488_CR50","doi-asserted-by":"publisher","first-page":"117553","DOI":"10.1016\/j.bcp.2025.117553","volume":"243","author":"S Tang","year":"2026","unstructured":"Tang, S. et al. LDHA facilitates immune escape in bladder cancer through H4K5 lactylation-dependent upregulation of PD-L1. Biochem. Pharm. 243, 117553 (2026).","journal-title":"Biochem. Pharm."},{"key":"1488_CR51","doi-asserted-by":"publisher","first-page":"113961","DOI":"10.1016\/j.jconrel.2025.113961","volume":"384","author":"X Shi","year":"2025","unstructured":"Shi, X. et al. Posttranslational remodeling micelle reverses cell-surface and exosomal PD-L1 immunosuppression in tumors resistant to PD-L1 antibody therapy. J. Control. Release 384, 113961 (2025).","journal-title":"J. Control. Release"},{"key":"1488_CR52","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3892\/ijmm.2017.3036","volume":"40","author":"F Ardito","year":"2017","unstructured":"Ardito, F., Giuliani, M., Perrone, D., Troiano, G. & Muzio, L. L. The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review). Int. J. Mol. Med. 40, 271\u2013280 (2017).","journal-title":"Int. J. Mol. Med."},{"key":"1488_CR53","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.tibs.2024.08.004","volume":"49","author":"T Houles","year":"2024","unstructured":"Houles, T., Yoon, S.-O. & Roux, P. P. The expanding landscape of canonical and non-canonical protein phosphorylation. Trends Biochem. Sci. 49, 986\u2013999 (2024).","journal-title":"Trends Biochem. Sci."},{"key":"1488_CR54","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1016\/j.ymthe.2023.07.021","volume":"31","author":"K Sun","year":"2023","unstructured":"Sun, K. et al. Targeting leucine-rich repeat serine\/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy. Mol. Ther. 31, 2929\u20132947 (2023).","journal-title":"Mol. Ther."},{"key":"1488_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24769-3","volume":"12","author":"X Zhang","year":"2021","unstructured":"Zhang, X. et al. NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. Nat. Commun. 12, 4536 (2021).","journal-title":"Nat. Commun."},{"key":"1488_CR56","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1158\/0008-5472.CAN-21-2300","volume":"82","author":"X Zhao","year":"2022","unstructured":"Zhao, X. et al. Phosphorylation and stabilization of PD-L1 by CK2 suppresses dendritic cell function. Cancer Res. 82, 2185\u20132195 (2022).","journal-title":"Cancer Res."},{"key":"1488_CR57","doi-asserted-by":"crossref","unstructured":"Du, L. et al. EGFR-induced and c-Src-mediated CD47 phosphorylation inhibits TRIM21-dependent polyubiquitylation and degradation of CD47 to promote tumor immune evasion. Adv. Sci. 10, e2206380 (2023).","DOI":"10.1002\/advs.202206380"},{"key":"1488_CR58","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1002\/1878-0261.12804","volume":"14","author":"F Meng","year":"2020","unstructured":"Meng, F., Su, Y. & Xu, B. Rho-associated protein kinase-dependent moesin phosphorylation is required for PD-L1 stabilization in breast cancer. Mol. Oncol. 14, 2701\u20132712 (2020).","journal-title":"Mol. Oncol."},{"key":"1488_CR59","doi-asserted-by":"crossref","unstructured":"Gou, Q. et al. Inhibition of CK2\/ING4 pathway facilitates non-small cell lung cancer immunotherapy. Adv. Sci. 10, e2304068 (2023).","DOI":"10.1002\/advs.202304068"},{"key":"1488_CR60","doi-asserted-by":"crossref","unstructured":"Liu, J. et al. FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer. J. Immunother. Cancer 10, e005116 (2022).","DOI":"10.1136\/jitc-2022-005116"},{"key":"1488_CR61","doi-asserted-by":"crossref","unstructured":"Wu, Y. et al. ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation. Nat. Commun. 12, 2346 (2021).","DOI":"10.1038\/s41467-021-22467-8"},{"key":"1488_CR62","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/0008-5472.CAN-21-2362","volume":"82","author":"W Jing","year":"2022","unstructured":"Jing, W. et al. FGFR3 destabilizes PD-L1 via NEDD4 to control T-cell-mediated bladder cancer immune surveillance. Cancer Res. 82, 114\u2013129 (2022).","journal-title":"Cancer Res."},{"key":"1488_CR63","doi-asserted-by":"crossref","unstructured":"He, M., Zhou, X. & Wang, X. Glycosylation: mechanisms, biological functions and clinical implications. Signal Transduct. Target. Ther. 9, 194 (2024).","DOI":"10.1038\/s41392-024-01886-1"},{"key":"1488_CR64","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1002\/cac2.12610","volume":"44","author":"X Xu","year":"2024","unstructured":"Xu, X. et al. Altered glycosylation in cancer: molecular functions and therapeutic potential. Cancer Commun. 44, 1316\u20131336 (2024).","journal-title":"Cancer Commun."},{"key":"1488_CR65","doi-asserted-by":"crossref","unstructured":"Wang, Y.-N., Lee, H.-H., Hsu, J. L., Yu, D. & Hung, M.-C. The impact of PD-L1\u2009N-linked glycosylation on cancer therapy and clinical diagnosis. J. Biomed. Sci. 27, 77 (2020).","DOI":"10.1186\/s12929-020-00670-x"},{"key":"1488_CR66","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/s41418-024-01432-0","volume":"32","author":"X Guo","year":"2024","unstructured":"Guo, X. et al. A STT3A-dependent PD-L1 glycosylation modification mediated by GMPS drives tumor immune evasion in hepatocellular carcinoma. Cell Death Differ. 32, 944\u2013958 (2024).","journal-title":"Cell Death Differ."},{"key":"1488_CR67","doi-asserted-by":"crossref","unstructured":"Shi, C. et al. Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation. Nat Commun. 13, 6951 (2022).","DOI":"10.1038\/s41467-022-34346-x"},{"key":"1488_CR68","doi-asserted-by":"publisher","first-page":"111942","DOI":"10.1016\/j.cellsig.2025.111942","volume":"134","author":"S Chong","year":"2025","unstructured":"Chong, S. et al. GALNT6 dual regulates innate immunity STING signaling and PD-L1 expression to promote immune evasion in pancreatic ductal adenocarcinoma. Cell. Signal. 134, 111942 (2025).","journal-title":"Cell. Signal."},{"key":"1488_CR69","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1038\/s41418-022-01012-0","volume":"29","author":"J Zhang","year":"2022","unstructured":"Zhang, J. et al. Loss of RBMS1 promotes anti-tumor immunity through enabling PD-L1 checkpoint blockade in triple-negative breast cancer. Cell Death Differ. 29, 2247\u20132261 (2022).","journal-title":"Cell Death Differ."},{"key":"1488_CR70","doi-asserted-by":"crossref","unstructured":"Li, C.-W. et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat. Commun. 7, 12632 (2016).","DOI":"10.1038\/ncomms12632"},{"key":"1488_CR71","doi-asserted-by":"crossref","unstructured":"Wang, D. et al. FAT4 overexpression promotes antitumor immunity by regulating the \u03b2-catenin\/STT3\/PD-L1 axis in cervical cancer. J. Exp. Clin. Cancer Res. 42, 222 (2023).","DOI":"10.1186\/s13046-023-02758-2"},{"key":"1488_CR72","doi-asserted-by":"crossref","unstructured":"Xiao, L. et al. B7 family protein glycosylation: promising novel targets in tumor treatment. Front. Immunol. 13, 1088560 (2022).","DOI":"10.3389\/fimmu.2022.1088560"},{"key":"1488_CR73","doi-asserted-by":"crossref","unstructured":"Duan, Z., Shi, R., Gao, B. & Cai, J. N-linked glycosylation of PD-L1\/PD-1: an emerging target for cancer diagnosis and treatment. J. Transl. Med. 22, 705 (2024).","DOI":"10.1186\/s12967-024-05502-2"},{"key":"1488_CR74","doi-asserted-by":"crossref","unstructured":"Granica, M., Laskowski, G., Link-Lenczowski, P. & Graczyk-Jarzynka, A. Modulation of N-glycosylation in the PD-1: PD-L1 axis as a strategy to enhance cancer immunotherapies. Biochim. Biophys. Acta Rev. Cancer 1880, 189274 (2025).","DOI":"10.1016\/j.bbcan.2025.189274"},{"key":"1488_CR75","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1158\/2159-8290.CD-20-0402","volume":"10","author":"X Song","year":"2020","unstructured":"Song, X. et al. Pharmacologic suppression of B7-H4 glycosylation restores antitumor immunity in immune-cold breast cancers. Cancer Discov. 10, 1872\u20131893 (2020).","journal-title":"Cancer Discov."},{"key":"1488_CR76","doi-asserted-by":"crossref","unstructured":"Wu, Z. et al. Coupled deglycosylation-ubiquitination cascade in regulating PD-1 degradation by MDM2. Cell Rep. 42, 112693 (2023).","DOI":"10.1016\/j.celrep.2023.112693"},{"key":"1488_CR77","doi-asserted-by":"crossref","unstructured":"Xu, Y. et al. PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy. J. Immunother. Cancer 9, e002699 (2021).","DOI":"10.1136\/jitc-2021-002699"},{"key":"1488_CR78","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202516863","volume":"13","author":"Y Cao","year":"2025","unstructured":"Cao, Y. et al. Core fucosylation represses SMURF1-dependent degradation of CD47 to promote tumor immune evasion. Adv. Sci. 13, e16863 (2025).","journal-title":"Adv. Sci."},{"key":"1488_CR79","doi-asserted-by":"crossref","unstructured":"Crawford, C. E. W. & Burslem, G. M. Acetylation: a new target for protein degradation in cancer. Trends Cancer. 11, 403\u2013420 (2025).","DOI":"10.1016\/j.trecan.2025.01.013"},{"key":"1488_CR80","doi-asserted-by":"crossref","unstructured":"Wang, C. & Ma, X. The role of acetylation and deacetylation in cancer metabolism. Clin. Transl. Med. 15, e70145 (2025).","DOI":"10.1002\/ctm2.70145"},{"key":"1488_CR81","doi-asserted-by":"crossref","unstructured":"Wang, H. et al. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1\/c-Jun\/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells. J. Exp. Clin. Cancer Res. 39, 29 (2020).","DOI":"10.1186\/s13046-020-1536-x"},{"key":"1488_CR82","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/path.6055","volume":"259","author":"YM Lee","year":"2023","unstructured":"Lee, Y. M. et al. SN-38, an active metabolite of irinotecan, enhances anti-PD-1 treatment efficacy in head and neck squamous cell carcinoma. J. Pathol. 259, 428\u2013440 (2023).","journal-title":"J. Pathol."},{"key":"1488_CR83","doi-asserted-by":"crossref","unstructured":"Song, S., Tang, H., Quan, W., Shang, A. & Ling, C. Estradiol initiates the immune escape of non-small cell lung cancer cells via ER\u03b2\/SIRT1\/FOXO3a\/PD-L1 axis. Int. Immunopharmacol. 107, 108629 (2022).","DOI":"10.1016\/j.intimp.2022.108629"},{"key":"1488_CR84","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.molmed.2024.05.005","volume":"30","author":"T Wang","year":"2024","unstructured":"Wang, T., Jiang, J., Zhang, X., Ke, X. & Qu, Y. Ubiquitin-like modification dependent proteasomal degradation and disease therapy. Trends Mol. Med. 30, 1061\u20131075 (2024).","journal-title":"Trends Mol. Med."},{"key":"1488_CR85","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.tibs.2020.11.005","volume":"46","author":"RM Vaughan","year":"2021","unstructured":"Vaughan, R. M., Kupai, A. & Rothbart, S. B. Chromatin regulation through ubiquitin and ubiquitin-like histone modifications. Trends Biochem. Sci. 46, 258\u2013269 (2021).","journal-title":"Trends Biochem. Sci."},{"key":"1488_CR86","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.7150\/thno.97162","volume":"14","author":"H Zhou","year":"2024","unstructured":"Zhou, H. et al. Distinctive tumorigenic significance and innovative oncology targets of SUMOylation. Theranostics 14, 3127\u20133149 (2024).","journal-title":"Theranostics"},{"key":"1488_CR87","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abq3362","volume":"16","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. SUMOylated IL-33 in the nucleus stabilizes the transcription factor IRF1 in hepatocellular carcinoma cells to promote immune escape. Sci. Signal. 16, eabq3362 (2023).","journal-title":"Sci. Signal."},{"key":"1488_CR88","doi-asserted-by":"crossref","unstructured":"Ma, X. et al. TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance. Signal Transduct. Target. Ther. 8, 246 (2023).","DOI":"10.1038\/s41392-023-01450-3"},{"key":"1488_CR89","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.7150\/ijbs.72244","volume":"18","author":"Z Liu","year":"2022","unstructured":"Liu, Z. et al. Emerging roles of protein palmitoylation and its modifying enzymes in cancer cell signal transduction and cancer therapy. Int. J. Biol. Sci. 18, 3447\u20133457 (2022).","journal-title":"Int. J. Biol. Sci."},{"key":"1488_CR90","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/1878-0261.13308","volume":"17","author":"B Zhou","year":"2022","unstructured":"Zhou, B., Hao, Q., Liang, Y. & Kong, E. Protein palmitoylation in cancer: molecular functions and therapeutic potential. Mol. Oncol. 17, 3\u201326 (2022).","journal-title":"Mol. Oncol."},{"key":"1488_CR91","doi-asserted-by":"crossref","unstructured":"Li, M., Zhang, L. & Chen, C. W. Diverse roles of protein palmitoylation in cancer progression, immunity, stemness, and beyond. Cells 12, 2209 (2023).","DOI":"10.3390\/cells12182209"},{"key":"1488_CR92","doi-asserted-by":"publisher","first-page":"101686","DOI":"10.1016\/j.xcrm.2024.101686","volume":"5","author":"C Chen","year":"2024","unstructured":"Chen, C. et al. Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8(+) T cell exhaustion and anti-PD-1 resistance. Cell Rep. Med. 5, 101686 (2024).","journal-title":"Cell Rep. Med."},{"key":"1488_CR93","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adp7302","volume":"9","author":"Z Zhang","year":"2024","unstructured":"Zhang, Z. et al. Palmitoylation of TIM-3 promotes immune exhaustion and restrains antitumor immunity. Sci. Immunol. 9, eadp7302 (2024).","journal-title":"Sci. Immunol."},{"key":"1488_CR94","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41551-019-0375-6","volume":"3","author":"H Yao","year":"2019","unstructured":"Yao, H. et al. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours. Nat. Biomed. Eng. 3, 306\u2013317 (2019).","journal-title":"Nat. Biomed. Eng."},{"key":"1488_CR95","doi-asserted-by":"publisher","first-page":"1531246","DOI":"10.3389\/fimmu.2025.1531246","volume":"16","author":"Z Ke","year":"2025","unstructured":"Ke, Z. et al. Emerging roles of mitochondrial sirtuin SIRT5 in succinylation modification and cancer development. Front. Immunol. 16, 1531246 (2025).","journal-title":"Front. Immunol."},{"key":"1488_CR96","doi-asserted-by":"publisher","first-page":"102242","DOI":"10.1016\/j.arr.2024.102242","volume":"95","author":"C Wang","year":"2024","unstructured":"Wang, C. et al. Role of succinylation modification in central nervous system diseases. Ageing Res. Rev. 95, 102242 (2024).","journal-title":"Ageing Res. Rev."},{"key":"1488_CR97","doi-asserted-by":"publisher","first-page":"781","DOI":"10.4103\/1673-5374.382229","volume":"19","author":"J Lian","year":"2024","unstructured":"Lian, J., Liu, W., Hu, Q. & Zhang, X. Succinylation modification: a potential therapeutic target in stroke. Neural Regen. Res. 19, 781\u2013787 (2024).","journal-title":"Neural Regen. Res."},{"key":"1488_CR98","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.gendis.2022.04.020","volume":"10","author":"Z Lu","year":"2023","unstructured":"Lu, Z. et al. OXCT1 regulates NF-\u03baB signaling pathway through \u03b2-hydroxybutyrate-mediated ketone body homeostasis in lung cancer. Genes Dis. 10, 352\u2013355 (2023).","journal-title":"Genes Dis."},{"key":"1488_CR99","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.molcel.2023.11.042","volume":"84","author":"W Ma","year":"2024","unstructured":"Ma, W. et al. OXCT1 functions as a succinyltransferase, contributing to hepatocellular carcinoma via succinylating LACTB. Mol. Cell 84, 538\u2013551.e537 (2024).","journal-title":"Mol. Cell"},{"key":"1488_CR100","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.molcel.2024.12.025","volume":"85","author":"D Guo","year":"2025","unstructured":"Guo, D. et al. OXCT1 succinylation and activation by SUCLA2 promotes ketolysis and liver tumor growth. Mol. Cell 85, 843\u2013856.e846 (2025).","journal-title":"Mol. Cell"},{"key":"1488_CR101","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s42003-025-08433-w","volume":"8","author":"H Zhang","year":"2025","unstructured":"Zhang, H. et al. OXCT1 promotes triple negative breast cancer immune escape via modulating succinylation modification of PGK1. Commun. Biol. 8, 1033 (2025).","journal-title":"Commun. Biol."},{"key":"1488_CR102","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-019-1678-1","volume":"574","author":"D Zhang","year":"2019","unstructured":"Zhang, D. et al. Metabolic regulation of gene expression by histone lactylation. Nature 574, 575\u2013580 (2019).","journal-title":"Nature"},{"key":"1488_CR103","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/j.ccell.2024.09.006","volume":"42","author":"H Li","year":"2024","unstructured":"Li, H., Sun, L., Gao, P. & Hu, H. Lactylation in cancer: current understanding and challenges. Cancer Cell 42, 1803\u20131807 (2024).","journal-title":"Cancer Cell"},{"key":"1488_CR104","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.7150\/ijbs.91492","volume":"20","author":"X Yu","year":"2024","unstructured":"Yu, X. et al. Histone lactylation: from tumor lactate metabolism to epigenetic regulation. Int. J. Biol. Sci. 20, 1833\u20131854 (2024).","journal-title":"Int. J. Biol. Sci."},{"key":"1488_CR105","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41392-024-02082-x","volume":"10","author":"J Chen","year":"2025","unstructured":"Chen, J. et al. Lactate and lactylation in cancer. Signal Transduct. Target. Ther. 10, 38 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1488_CR106","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.cpt.2024.09.006","volume":"3","author":"X Hu","year":"2025","unstructured":"Hu, X. et al. Claudin-9 (CLDN9) promotes gastric cancer progression by enhancing the glycolysis pathway and facilitating PD-L1 lactylation to suppress CD8+ T cell anti-tumor immunity. Cancer Pathog. Ther. 3, 253\u2013266 (2025).","journal-title":"Cancer Pathog. Ther."},{"key":"1488_CR107","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1016\/j.cmet.2024.10.019","volume":"36","author":"H Tong","year":"2024","unstructured":"Tong, H. et al. Dual impacts of serine\/glycine-free diet in enhancing antitumor immunity and promoting evasion via PD-L1 lactylation. Cell Metab. 36, 2493\u20132510.e2499 (2024).","journal-title":"Cell Metab."},{"key":"1488_CR108","doi-asserted-by":"crossref","unstructured":"Cai, J. et al. Lactylation-driven NUPR1 promotes immunosuppression of tumor-infiltrating macrophages in hepatocellular carcinoma. Adv. Sci. 12, e2413095 (2025).","DOI":"10.1002\/advs.202413095"},{"key":"1488_CR109","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41392-023-01605-2","volume":"8","author":"ZW Huang","year":"2023","unstructured":"Huang, Z. W. et al. STAT5 promotes PD-L1 expression by facilitating histone lactylation to drive immunosuppression in acute myeloid leukemia. Signal Transduct. Target. Ther. 8, 391 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1488_CR110","doi-asserted-by":"crossref","unstructured":"Rao, K. et al. Lactylation orchestrates ubiquitin-independent degradation of cGAS and promotes tumor growth. Cell Rep. 44, 115441 (2025).","DOI":"10.1016\/j.celrep.2025.115441"},{"key":"1488_CR111","doi-asserted-by":"publisher","first-page":"795","DOI":"10.4049\/jimmunol.2300758","volume":"213","author":"J Zhang","year":"2024","unstructured":"Zhang, J. et al. Mitochondrial DNA programs lactylation of cGAS to induce IFN responses in patients with systemic Lupus erythematosus. J. Immunol. 213, 795\u2013807 (2024).","journal-title":"J. Immunol."},{"key":"1488_CR112","doi-asserted-by":"crossref","unstructured":"Liang, L. et al. Lactylation stabilizes PD-L1 to promote tumor immune evasion and cell growth. Cell Death Dis. 17, 335 (2026).","DOI":"10.1038\/s41419-026-08589-1"},{"key":"1488_CR113","doi-asserted-by":"crossref","unstructured":"Liu, S. et al. Lactylation-driven MVP upregulation boosts immunotherapy resistance by inhibiting PD-L1 degradation in hepatocellular carcinoma. J. Immunother. Cancer 13, e012230 (2025).","DOI":"10.1136\/jitc-2025-012230"},{"key":"1488_CR114","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1158\/2159-8290.CD-24-1232","volume":"15","author":"NJ Song","year":"2025","unstructured":"Song, N. J. et al. Tumor-associated NK cells regulate distinct CD8+ T-cell differentiation program in cancer and contribute to resistance against immune checkpoint blockers. Cancer Discov. 15, 1835\u20131857 (2025).","journal-title":"Cancer Discov."},{"key":"1488_CR115","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ads8597","volume":"11","author":"WF Qu","year":"2025","unstructured":"Qu, W. F. et al. Targeting HMGB2 acts as dual immunomodulator by bolstering CD8(+) T cell function and inhibiting tumor growth in hepatocellular carcinoma. Sci. Adv. 11, eads8597 (2025).","journal-title":"Sci. Adv."},{"key":"1488_CR116","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.immuni.2022.12.008","volume":"56","author":"J Park","year":"2023","unstructured":"Park, J., Hsueh, P.-C., Li, Z. & Ho, P.-C. Microenvironment-driven metabolic adaptations guiding CD8+ T cell anti-tumor immunity. Immunity 56, 32\u201342 (2023).","journal-title":"Immunity"},{"key":"1488_CR117","doi-asserted-by":"crossref","unstructured":"Xia, X. et al. Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy. Mol Cancer 23, 175 (2024).","DOI":"10.1186\/s12943-024-02079-8"},{"key":"1488_CR118","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.trecan.2024.07.009","volume":"10","author":"E Montauti","year":"2024","unstructured":"Montauti, E., Oh, D. Y. & Fong, L. CD4+ T cells in antitumor immunity. Trends Cancer 10, 969\u2013985 (2024).","journal-title":"Trends Cancer"},{"key":"1488_CR119","doi-asserted-by":"crossref","unstructured":"Zhou, R. et al. CD155 and its receptors in cancer immune escape and immunotherapy. Cancer Lett. 573, 216381 (2023).","DOI":"10.1016\/j.canlet.2023.216381"},{"key":"1488_CR120","doi-asserted-by":"crossref","unstructured":"Zhan, M. et al. CD155 in tumor progression and targeted therapy. Cancer Lett. 545, 215830 (2022).","DOI":"10.1016\/j.canlet.2022.215830"},{"key":"1488_CR121","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1038\/s12276-024-01317-9","volume":"56","author":"Y Jo","year":"2024","unstructured":"Jo, Y., Sim, H. I., Yun, B., Park, Y. & Jin, H. S. Revisiting T-cell adhesion molecules as potential targets for cancer immunotherapy: CD226 and CD2. Exp. Mol. Med. 56, 2113\u20132126 (2024).","journal-title":"Exp. Mol. Med."},{"key":"1488_CR122","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.immuni.2020.09.010","volume":"53","author":"M Braun","year":"2020","unstructured":"Braun, M. et al. CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8+ T cells. Immunity 53, 805\u2013823.e815 (2020).","journal-title":"Immunity"},{"key":"1488_CR123","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2307150121","volume":"121","author":"B Dong","year":"2024","unstructured":"Dong, B. et al. RNF20 contributes to epigenetic immunosuppression through CDK9-dependent LSD1 stabilization. Proc. Natl. Acad. Sci. USA 121, e2307150121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1488_CR124","doi-asserted-by":"publisher","first-page":"2001417","DOI":"10.1002\/advs.202001417","volume":"7","author":"Y Bei","year":"2020","unstructured":"Bei, Y. et al. CDK5 inhibition abrogates TNBC stem-cell property and enhances anti-PD-1 therapy. Adv. Sci. 7, 2001417 (2020).","journal-title":"Adv. Sci."},{"key":"1488_CR125","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.neo.2020.07.004","volume":"22","author":"AL Remoli","year":"2020","unstructured":"Remoli, A. L. et al. I\u03baB kinase-\u03b5-mediated phosphorylation triggers IRF-1 degradation in breast cancer cells. Neoplasia 22, 459\u2013469 (2020).","journal-title":"Neoplasia"},{"key":"1488_CR126","doi-asserted-by":"crossref","unstructured":"Huang, S.-Y. et al. PJA1-mediated suppression of pyroptosis as a driver of docetaxel resistance in nasopharyngeal carcinoma. Nat. Commun. 15, 215830 (2024).","DOI":"10.1038\/s41467-024-49675-2"},{"key":"1488_CR127","doi-asserted-by":"crossref","unstructured":"Liu, G. & Luo, P. Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy. Front. Immunol. 14, 1208788 (2023).","DOI":"10.3389\/fimmu.2023.1208788"},{"key":"1488_CR128","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1111\/febs.16383","volume":"289","author":"R Sun","year":"2022","unstructured":"Sun, R. & Lim, S. O. FBXL20-mediated ubiquitination triggers the proteasomal degradation of 4-1BB. FEBS J. 289, 4549\u20134563 (2022).","journal-title":"FEBS J."},{"key":"1488_CR129","doi-asserted-by":"publisher","first-page":"1337478","DOI":"10.3389\/fimmu.2024.1337478","volume":"15","author":"Y Chen","year":"2024","unstructured":"Chen, Y., Li, Y. & Wu, L. Protein S-palmitoylation modification: implications in tumor and tumor immune microenvironment. Front. Immunol. 15, 1337478 (2024).","journal-title":"Front. Immunol."},{"key":"1488_CR130","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56344-5","volume":"16","author":"B Huang","year":"2025","unstructured":"Huang, B. et al. Palmitoylation-dependent regulation of GPX4 suppresses ferroptosis. Nat. Commun. 16, 867 (2025).","journal-title":"Nat. Commun."},{"key":"1488_CR131","doi-asserted-by":"crossref","unstructured":"Liu, L. et al. Acyltransferase zinc finger DHHC-type containing 2 aggravates gastric carcinoma growth by targeting Nrf2 signaling: a mechanism-based multicombination bionic nano-drug therapy. Redox Biol. 70, 103051 (2024).","DOI":"10.1016\/j.redox.2024.103051"},{"key":"1488_CR132","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41401-024-01248-1","volume":"45","author":"B Lu","year":"2024","unstructured":"Lu, B. et al. zDHHC20-driven S-palmitoylation of CD80 is required for its costimulatory function. Acta Pharmacol. Sin. 45, 1214\u20131223 (2024).","journal-title":"Acta Pharmacol. Sin."},{"key":"1488_CR133","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-023-00846-y","volume":"21","author":"SA Lasser","year":"2024","unstructured":"Lasser, S. A., Ozbay Kurt, F. G., Arkhypov, I., Utikal, J. & Umansky, V. Myeloid-derived suppressor cells in cancer and cancer therapy. Nat. Rev. Clin. Oncol. 21, 147\u2013164 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1488_CR134","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02208-3","volume":"24","author":"S He","year":"2025","unstructured":"He, S. & Qi, Z. L. C. Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy. Mol. Cancer 24, 5 (2025).","journal-title":"Mol. Cancer"},{"key":"1488_CR135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-024-01364-2","volume":"57","author":"J Kim","year":"2025","unstructured":"Kim, J. et al. Trogocytosis-mediated immune evasion in the tumor microenvironment. Exp. Mol. Med. 57, 1\u201312 (2025).","journal-title":"Exp. Mol. Med."},{"key":"1488_CR136","doi-asserted-by":"crossref","unstructured":"Shen, Y. et al. Ursodeoxycholic acid reduces antitumor immunosuppression by inducing CHIP-mediated TGF-\u03b2 degradation. Nat. Commun. 13, 3419 (2022).","DOI":"10.1038\/s41467-022-31141-6"},{"key":"1488_CR137","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.jare.2024.12.043","volume":"76","author":"YE Liu","year":"2025","unstructured":"Liu, Y. E. et al. Targeting macrophages in cancer immunotherapy: Frontiers and challenges. J. Adv. Res. 76, 695\u2013713 (2025).","journal-title":"J. Adv. Res."},{"key":"1488_CR138","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1111\/jgh.70015","volume":"40","author":"C Liu","year":"2025","unstructured":"Liu, C. et al. m6A modification-mediated regulation of DCAF13 promotes glycolytic metabolism and drives hepatocellular carcinoma progression via interaction with G6PD. J. Gastroenterol. Hepatol. 40, 2311\u20132323 (2025).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"1488_CR139","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","volume":"8","author":"C Xue","year":"2023","unstructured":"Xue, C. et al. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct. Target. Ther. 8, 204 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1488_CR140","doi-asserted-by":"publisher","first-page":"523","DOI":"10.2147\/ITT.S485670","volume":"14","author":"S Parveen","year":"2025","unstructured":"Parveen, S., Fatma, M., Mir, S. S., Dermime, S. & Uddin, S. JAK-STAT signaling in autoimmunity and cancer. Immunotargets Ther. 14, 523\u2013554 (2025).","journal-title":"Immunotargets Ther."},{"key":"1488_CR141","doi-asserted-by":"crossref","unstructured":"Awasthi, N., Liongue, C. & Ward, A. C. STAT proteins: a kaleidoscope of canonical and non-canonical functions in immunity and cancer. J. Hematol. Oncol. 14, 198 (2021).","DOI":"10.1186\/s13045-021-01214-y"},{"key":"1488_CR142","doi-asserted-by":"crossref","unstructured":"Ao, Y. Q. et al. ASCC3 promotes the immunosuppression and progression of non-small cell lung cancer by impairing the type I interferon response via CAND1-mediated ubiquitination inhibition of STAT3. J. Immunother. Cancer 11, e007766 (2023).","DOI":"10.1136\/jitc-2023-007766"},{"key":"1488_CR143","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01258-7","volume":"19","author":"S Zou","year":"2020","unstructured":"Zou, S. et al. Targeting STAT3 in cancer immunotherapy. Mol. Cancer 19, 145 (2020).","journal-title":"Mol. Cancer"},{"key":"1488_CR144","doi-asserted-by":"publisher","first-page":"649020","DOI":"10.3389\/fimmu.2021.649020","volume":"12","author":"G Song","year":"2021","unstructured":"Song, G. et al. TRAF6 regulates the immunosuppressive effects of myeloid-derived suppressor cells in tumor-bearing host. Front. Immunol. 12, 649020 (2021).","journal-title":"Front. Immunol."},{"key":"1488_CR145","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/sj.onc.1210904","volume":"27","author":"B Huang","year":"2008","unstructured":"Huang, B., Zhao, J., Unkeless, J. C., Feng, Z. H. & Xiong, H. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 27, 218\u2013224 (2008).","journal-title":"Oncogene"},{"key":"1488_CR146","doi-asserted-by":"publisher","first-page":"6530","DOI":"10.7150\/thno.44417","volume":"10","author":"B Zhou","year":"2020","unstructured":"Zhou, B. et al. Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinoma. Theranostics 10, 6530\u20136543 (2020).","journal-title":"Theranostics"},{"key":"1488_CR147","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-08198-4","volume":"16","author":"Z Zhang","year":"2025","unstructured":"Zhang, Z. et al. TREM2 facilitates gastric cancer progression and immune evasion via inhibiting TRIM21-mediated STAT1 degradation in tumor-associated macrophages. Cell Death Dis. 16, 845 (2025).","journal-title":"Cell Death Dis."},{"key":"1488_CR148","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/cac2.70045","volume":"45","author":"E Chen","year":"2025","unstructured":"Chen, E. et al. NAT10 regulates tumor progression and immune microenvironment in pancreatic ductal adenocarcinoma via the N4-acetylated LAMB3-mediated FAK\/ERK pathway. Cancer Commun. 45, 1162\u20131187 (2025).","journal-title":"Cancer Commun."},{"key":"1488_CR149","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60293-4","volume":"16","author":"WC Liu","year":"2025","unstructured":"Liu, W. C. et al. Inhibition of tumor-intrinsic NAT10 enhances antitumor immunity by triggering type I interferon response via MYC\/CDK2\/DNMT1 pathway. Nat. Commun. 16, 5154 (2025).","journal-title":"Nat. Commun."},{"key":"1488_CR150","doi-asserted-by":"crossref","unstructured":"Yu, T. et al. Modulation of M2 macrophage polarization by the crosstalk between Stat6 and Trim24. Nat. Commun. 10, 4353 (2019).","DOI":"10.1038\/s41467-019-12384-2"},{"key":"1488_CR151","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf0992","volume":"14","author":"S Shang","year":"2022","unstructured":"Shang, S. et al. TRIB3 reduces CD8(+) T cell infiltration and induces immune evasion by repressing the STAT1-CXCL10 axis in colorectal cancer. Sci. Transl. Med. 14, eabf0992 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1488_CR152","doi-asserted-by":"crossref","unstructured":"Li, W. et al. Exosomal Biglycan promotes gastric cancer progression via M2 polarization and CXCL10-mediated JAK\/STAT1 activation. Cancer Lett. 626, 217758 (2025).","DOI":"10.1016\/j.canlet.2025.217758"},{"key":"1488_CR153","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/imr.13272","volume":"321","author":"P Holicek","year":"2024","unstructured":"Holicek, P. et al. Type I interferon and cancer. Immunol. Rev. 321, 115\u2013127 (2024).","journal-title":"Immunol. Rev."},{"key":"1488_CR154","doi-asserted-by":"crossref","unstructured":"Li, G. et al. cGAS-STING pathway mediates activation of dendritic cell sensing of immunogenic tumors. Cell. Mol. Life Sci. 81, 149 (2024).","DOI":"10.1007\/s00018-024-05191-6"},{"key":"1488_CR155","doi-asserted-by":"crossref","unstructured":"Zeng, Q. et al. ORMDL3 restrains type I interferon signaling and anti-tumor immunity by promoting RIG-I degradation. Elife. 13, RP101973 (2025).","DOI":"10.7554\/eLife.101973"},{"key":"1488_CR156","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1016\/j.molcel.2023.10.043","volume":"83","author":"G Zhang","year":"2023","unstructured":"Zhang, G. et al. CPT1A induction following epigenetic perturbation promotes MAVS palmitoylation and activation to potentiate antitumor immunity. Mol. Cell 83, 4370\u20134385.e4379 (2023).","journal-title":"Mol. Cell"},{"key":"1488_CR157","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1016\/j.apsb.2023.04.001","volume":"13","author":"Q Xie","year":"2023","unstructured":"Xie, Q. et al. Activation of insulin-like growth factor-1 receptor (IGF-1R) promotes growth of colorectal cancer through triggering the MEX3A-mediated degradation of RIG-I. Acta Pharm.Sin. B. 13, 2963\u20132975 (2023).","journal-title":"Acta Pharm.Sin. B."},{"key":"1488_CR158","doi-asserted-by":"publisher","first-page":"3775","DOI":"10.1021\/acsinfecdis.4c00213","volume":"10","author":"V Singh","year":"2024","unstructured":"Singh, V. et al. UBR7 E3 ligase suppresses interferon-\u03b2 mediated immune signaling by targeting Sp110 in hepatitis B virus-induced hepatocellular carcinoma. ACS Infect. Dis. 10, 3775\u20133796 (2024).","journal-title":"ACS Infect. Dis."},{"key":"1488_CR159","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/s41423-025-01310-w","volume":"22","author":"H Mao","year":"2025","unstructured":"Mao, H., Zhao, X. & Sun, S. C. NF-\u03baB in inflammation and cancer. Cell. Mol. Immunol. 22, 811\u2013839 (2025).","journal-title":"Cell. Mol. Immunol."},{"key":"1488_CR160","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","volume":"9","author":"Q Guo","year":"2024","unstructured":"Guo, Q. et al. NF-\u03baB in biology and targeted therapy: new insights and translational implications. Signal Transduct. Target. Ther. 9, 53 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1488_CR161","doi-asserted-by":"crossref","unstructured":"Zhang, Z. et al. PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK\/NF-\u03baB pathway and PD-L1 expression. J. Immunother. Cancer 11, e007627 (2023).","DOI":"10.1136\/jitc-2023-007627"},{"key":"1488_CR162","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06656-z","volume":"15","author":"Y Yang","year":"2024","unstructured":"Yang, Y. et al. GATA4 regulates the transcription of MMP9 to suppress the invasion and migration of breast cancer cells via HDAC1-mediated p65 deacetylation. Cell Death Dis. 15, 289 (2024).","journal-title":"Cell Death Dis."},{"key":"1488_CR163","doi-asserted-by":"crossref","unstructured":"Lin, X.-T. et al. Elevated FBXW10 drives hepatocellular carcinoma tumorigenesis via AR-VRK2 phosphorylation-dependent GAPDH ubiquitination in male transgenic mice. Cell Rep. 42, 112812 (2023).","DOI":"10.1016\/j.celrep.2023.112812"},{"key":"1488_CR164","doi-asserted-by":"publisher","first-page":"1418025","DOI":"10.3389\/fimmu.2024.1418025","volume":"15","author":"J Zhou","year":"2024","unstructured":"Zhou, J., Zhang, L., Liu, S., DeRubeis, D. & Zhang, D. Toll-like receptors in breast cancer immunity and immunotherapy. Front. Immunol. 15, 1418025 (2024).","journal-title":"Front. Immunol."},{"key":"1488_CR165","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.549","volume":"5","author":"K Wang","year":"2024","unstructured":"Wang, K., Huang, H., Zhan, Q., Ding, H. & Li, Y. Toll-like receptors in health and disease. MedComm (2020) 5, e549 (2024).","journal-title":"MedComm (2020)"},{"key":"1488_CR166","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-08266-9","volume":"16","author":"JH Shin","year":"2025","unstructured":"Shin, J. H. et al. USP11 promotes colorectal cancer progression by stabilizing EGFR and TRAF6: a potential therapeutic target in EGFR- and TLR-driven tumorigenesis. Cell Death Dis. 16, 894 (2025).","journal-title":"Cell Death Dis."},{"key":"1488_CR167","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41418-023-01115-2","volume":"30","author":"J Zhang","year":"2023","unstructured":"Zhang, J. et al. E3 ligase RNF99 negatively regulates TLR-mediated inflammatory immune response via K48-linked ubiquitination of TAB2. Cell Death Differ. 30, 966\u2013978 (2023).","journal-title":"Cell Death Differ."},{"key":"1488_CR168","doi-asserted-by":"crossref","unstructured":"Zhang, Z. D. et al. RNF115 inhibits the post-ER Trafficking of TLRs and TLRs-mediated immune responses by catalyzing K11-linked ubiquitination of RAB1A and RAB13. Adv. Sci. 9, e2105391 (2022).","DOI":"10.1002\/advs.202105391"},{"key":"1488_CR169","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41590-021-00896-3","volume":"22","author":"M Takahashi","year":"2021","unstructured":"Takahashi, M. et al. The tumor suppressor kinase DAPK3 drives tumor-intrinsic immunity through the STING\u2013IFN-\u03b2 pathway. Nat. Immunol. 22, 485\u2013496 (2021).","journal-title":"Nat. Immunol."},{"key":"1488_CR170","doi-asserted-by":"publisher","first-page":"8393","DOI":"10.1158\/0008-5472.CAN-08-1915","volume":"68","author":"G Wu","year":"2008","unstructured":"Wu, G. et al. Small molecule targeting the Hec1\/Nek2 mitotic pathway suppresses tumor cell growth in culture and in animal. Cancer Res. 68, 8393\u20138399 (2008).","journal-title":"Cancer Res."},{"key":"1488_CR171","doi-asserted-by":"crossref","unstructured":"Wu, S.-T. et al. NEK2 regulates B cell function and the severity of experimental autoimmune encephalomyelitis. J. Neuroinflammation 22, 152 (2025).","DOI":"10.1186\/s12974-025-03472-w"},{"key":"1488_CR172","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/hep.32804","volume":"77","author":"MJ Borad","year":"2023","unstructured":"Borad, M. J. et al. Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced\/metastatic cholangiocarcinoma: a Phase 1b\/2 study. Hepatology 77, 760\u2013773 (2023).","journal-title":"Hepatology"},{"key":"1488_CR173","unstructured":"Biosciences, S. Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients with Basal Cell Carcinoma (BCC). ClinicalTrials.gov. NCT03897036 (2025)."},{"key":"1488_CR174","unstructured":"Giselle Sholler, M. S. Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors. ClinicalTrials.gov. NCT06541262 (2025)."},{"key":"1488_CR175","doi-asserted-by":"crossref","unstructured":"Zhang, D. et al. Pharmacological suppression of HHLA2 glycosylation restores anti-tumor immunity in colorectal cancer. Cancer Lett. 589, 216819 (2024).","DOI":"10.1016\/j.canlet.2024.216819"},{"key":"1488_CR176","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41368-024-00311-1","volume":"16","author":"S Xu","year":"2024","unstructured":"Xu, S. et al. Stabilization of EREG via STT3B-mediated N-glycosylation is critical for PDL1 upregulation and immune evasion in head and neck squamous cell carcinoma. Int. J. Oral Sci. 16, 47 (2024).","journal-title":"Int. J. Oral Sci."},{"key":"1488_CR177","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.4049\/jimmunol.1900937","volume":"204","author":"S Sasawatari","year":"2020","unstructured":"Sasawatari, S., Okamoto, Y., Kumanogoh, A. & Toyofuku, T. Blockade of N-glycosylation promotes antitumor immune response of T cells. J. Immunol. 204, 1373\u20131385 (2020).","journal-title":"J. Immunol."},{"key":"1488_CR178","doi-asserted-by":"crossref","unstructured":"Zhang, R. et al. D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1. Proc. Natl. Acad. Sci. USA. 119, e2114851119 (2022).","DOI":"10.1073\/pnas.2114851119"},{"key":"1488_CR179","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nature24028","volume":"550","author":"LM Lasko","year":"2017","unstructured":"Lasko, L. M. et al. Discovery of a selective catalytic p300\/CBP inhibitor that targets lineage-specific tumours. Nature 550, 128\u2013132 (2017).","journal-title":"Nature"},{"key":"1488_CR180","doi-asserted-by":"crossref","unstructured":"Hu, L. et al. Chemotherapy-induced pyroptosis is mediated by BAK\/BAX-caspase-3-GSDME pathway and inhibited by 2-bromopalmitate. Cell Death Dis. 11, 281 (2020).","DOI":"10.1038\/s41419-020-2476-2"},{"key":"1488_CR181","doi-asserted-by":"publisher","first-page":"101357","DOI":"10.1016\/j.xcrm.2023.101357","volume":"5","author":"Q Wang","year":"2024","unstructured":"Wang, Q. et al. Benzosceptrin C induces lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting DHHC3. Cell Rep. Med. 5, 101357 (2024).","journal-title":"Cell Rep. Med."},{"key":"1488_CR182","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1136\/gutjnl-2021-324834","volume":"71","author":"S Kumar","year":"2022","unstructured":"Kumar, S. et al. Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model. Gut. 71, 2266\u20132283 (2022).","journal-title":"Gut."},{"key":"1488_CR183","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aba7791","volume":"13","author":"ES Lightcap","year":"2021","unstructured":"Lightcap, E. S. et al. A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models. Sci. Transl. Med. 13, eaba7791 (2021).","journal-title":"Sci. Transl. Med."},{"key":"1488_CR184","doi-asserted-by":"crossref","unstructured":"Ou, X., Gao, G., Habaz, I. A. & Wang, Y. Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies. MedComm (2020) 5, e694 (2024).","DOI":"10.1002\/mco2.694"},{"key":"1488_CR185","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.drudis.2019.12.001","volume":"25","author":"S Tadesse","year":"2020","unstructured":"Tadesse, S. et al. Targeting CDK2 in cancer: challenges and opportunities for therapy. Drug Discov. Today 25, 406\u2013413 (2020).","journal-title":"Drug Discov. Today"},{"key":"1488_CR186","doi-asserted-by":"crossref","unstructured":"Hashemi, M. et al. Advances in RNAi therapies for gastric cancer: targeting drug resistance and nanoscale delivery. Biomed. Pharmacother. 169, 115927 (2023).","DOI":"10.1016\/j.biopha.2023.115927"},{"key":"1488_CR187","doi-asserted-by":"crossref","unstructured":"Ma, H., Li, R.-F. & Yu, Z.-L. Micro\/nanomotors in targeted drug delivery: advances, challenges, and future directions. Int. J. Pharm. 674, 125471 (2025).","DOI":"10.1016\/j.ijpharm.2025.125471"},{"key":"1488_CR188","doi-asserted-by":"publisher","first-page":"114100","DOI":"10.1016\/j.colsurfb.2024.114100","volume":"242","author":"C Wang","year":"2024","unstructured":"Wang, C., Wang, B., Zhang, Q. & Zhang, S. Tumor microenvironment-responsive cell-penetrating peptides: design principle and precision delivery. Colloids Surf. B Biointerfaces 242, 114100 (2024).","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"1488_CR189","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.tips.2017.01.003","volume":"38","author":"G Guidotti","year":"2017","unstructured":"Guidotti, G., Brambilla, L. & Rossi, D. Cell-penetrating peptides: from basic research to clinics. Trends Pharm. Sci. 38, 406\u2013424 (2017).","journal-title":"Trends Pharm. Sci."},{"key":"1488_CR190","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.actbio.2025.02.056","volume":"196","author":"C-Y Lin","year":"2025","unstructured":"Lin, C.-Y. et al. Dual cell-penetrating peptide-conjugated polymeric nanocarriers for miRNA-205\u20135p delivery in gene therapy of cutaneous squamous cell carcinoma. Acta Biomater. 196, 332\u2013349 (2025).","journal-title":"Acta Biomater."},{"key":"1488_CR191","doi-asserted-by":"crossref","unstructured":"Shi, Y.-Y. et al. Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates. Cell Death Dis. 15, 701 (2024).","DOI":"10.1038\/s41419-024-07182-8"},{"key":"1488_CR192","doi-asserted-by":"crossref","unstructured":"Zeng, S. et al. Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: recent progress and future challenges. Eur. J. Med. Chem. 210, 112981 (2021).","DOI":"10.1016\/j.ejmech.2020.112981"},{"key":"1488_CR193","doi-asserted-by":"crossref","unstructured":"Moon, Y. et al. Self-assembled peptide-derived Proteolysis-Targeting Chimera (PROTAC) nanoparticles for tumor-targeted and durable PD-L1 degradation in cancer immunotherapy. Angew. Chem. Int. Ed. Engl. 64, e202414146 (2024).","DOI":"10.1002\/anie.202414146"},{"key":"1488_CR194","doi-asserted-by":"crossref","unstructured":"Yao, Y. et al. An Oral PROTAC targeting HPK1 degradation potentiates anti-solid tumor immunity. Adv. Mater. 37, e2411454 (2024).","DOI":"10.1002\/adma.202411454"},{"key":"1488_CR195","doi-asserted-by":"crossref","unstructured":"Wang, L. et al. PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. J. Exp. Med. 221, e20231519 (2024).","DOI":"10.1158\/1538-7445.AM2024-2469"},{"key":"1488_CR196","doi-asserted-by":"publisher","first-page":"13852","DOI":"10.1021\/acs.jmedchem.4c00644","volume":"67","author":"M Wu","year":"2024","unstructured":"Wu, M. et al. Discovery of an exceptionally orally bioavailable and potent HPK1 PROTAC with enhancement of antitumor efficacy of anti-PD-L1 therapy. J. Med. Chem. 67, 13852\u201313878 (2024).","journal-title":"J. Med. Chem."},{"key":"1488_CR197","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","volume":"17","author":"GT Gibney","year":"2016","unstructured":"Gibney, G. T., Weiner, L. M. & Atkins, M. B. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 17, e542\u2013e551 (2016).","journal-title":"Lancet Oncol."},{"key":"1488_CR198","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.canlet.2017.11.014","volume":"414","author":"F Teng","year":"2018","unstructured":"Teng, F., Meng, X., Kong, L. & Yu, J. Progress and challenges of predictive biomarkers of anti PD-1\/PD-L1 immunotherapy: a systematic review. Cancer Lett. 414, 166\u2013173 (2018).","journal-title":"Cancer Lett."},{"key":"1488_CR199","doi-asserted-by":"crossref","unstructured":"Xu, J. et al. Removal of N-linked glycosylation enhances PD-L1 detection in colon cancer: validation research based on immunohistochemistry analysis. Technol. Cancer Res. Treat. 20, 15330338211019442 (2021).","DOI":"10.1177\/15330338211019442"},{"key":"1488_CR200","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ccell.2019.06.008","volume":"36","author":"H-H Lee","year":"2019","unstructured":"Lee, H.-H. et al. Removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1\/PD-L1 therapeutic efficacy. Cancer Cell 36, 168\u2013178.e164 (2019).","journal-title":"Cancer Cell"},{"key":"1488_CR201","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01304-4","volume":"20","author":"J Mei","year":"2021","unstructured":"Mei, J. et al. A comparability study of natural and deglycosylated PD-L1 levels in lung cancer: evidence from immunohistochemical analysis. Mol. Cancer 20, 11 (2021).","journal-title":"Mol. Cancer"},{"key":"1488_CR202","doi-asserted-by":"publisher","first-page":"217912","DOI":"10.1016\/j.canlet.2025.217912","volume":"631","author":"SC Wang","year":"2025","unstructured":"Wang, S. C. et al. Deglycosylated PD-L1 is a biomarker for immune checkpoint blockade response: a real-world study in breast cancer patients in Taiwan. Cancer Lett. 631, 217912 (2025).","journal-title":"Cancer Lett."},{"key":"1488_CR203","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02477-6","volume":"24","author":"YT Liu","year":"2025","unstructured":"Liu, Y. T. et al. Turning cold tumors into hot tumors to ignite immunotherapy. Mol. Cancer 24, 254 (2025).","journal-title":"Mol. Cancer"},{"key":"1488_CR204","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.molcel.2019.10.015","volume":"77","author":"Y Zhu","year":"2020","unstructured":"Zhu, Y. et al. Dynamic Regulation of ME1 phosphorylation and acetylation affects lipid metabolism and colorectal tumorigenesis. Mol. Cell 77, 138\u2013149.e135 (2020).","journal-title":"Mol. Cell"},{"key":"1488_CR205","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adx6489","volume":"11","author":"G Wu","year":"2025","unstructured":"Wu, G. et al. Metabolism-driven posttranslational modifications and immune regulation: emerging targets for immunotherapy. Sci. Adv. 11, eadx6489 (2025).","journal-title":"Sci. Adv."},{"key":"1488_CR206","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.plrev.2025.10.001","volume":"55","author":"H Zhang","year":"2025","unstructured":"Zhang, H. et al. Protein post-translational modifications and tumor immunity: A pan-cancer perspective. Phys. Life Rev. 55, 142\u2013209 (2025).","journal-title":"Phys. Life Rev."},{"key":"1488_CR207","doi-asserted-by":"publisher","first-page":"1537615","DOI":"10.3389\/fimmu.2025.1537615","volume":"16","author":"K Matsumoto","year":"2025","unstructured":"Matsumoto, K., Matsumoto, Y. & Wada, J. PARylation-mediated post-transcriptional modifications in cancer immunity and immunotherapy. Front. Immunol. 16, 1537615 (2025).","journal-title":"Front. Immunol."},{"key":"1488_CR208","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1038\/s44318-024-00125-1","volume":"43","author":"VC Ribeiro","year":"2024","unstructured":"Ribeiro, V. C., Russo, L. C. & Hoch, N. C. PARP14 is regulated by the PARP9\/DTX3L complex and promotes interferon \u03b3-induced ADP-ribosylation. EMBO J. 43, 2908\u20132928 (2024).","journal-title":"EMBO J."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01488-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01488-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01488-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:02:43Z","timestamp":1786320163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01488-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":208,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1488"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01488-w","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All authors have agreed to publish this manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"306"}}